Results 221 to 230 of about 953,563 (287)

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

open access: yesAndrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli   +7 more
wiley   +1 more source

Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner   +2 more
wiley   +1 more source

Clinical Features and Predictors of Hospital Stay in Paediatric Epstein–Barr Virus Infectious Mononucleosis: A Multicentre Cohort Study

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim To describe age‐specific clinical features and identify predictors of length of hospital stay in children and adolescents with primary Epstein–Barr virus (EBV) infectious mononucleosis (IM). Methods This multicentre retrospective cohort study included all children and adolescents aged 0–17 years with a verified primary EBV infection in the
Lasse H. Nyhegn   +5 more
wiley   +1 more source

Psychiatric and Neurodevelopmental Outcomes in Swedish Children With Hearing Loss due to Congenital Cytomegalovirus Infection: A Cross‐Sectional Study

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim To investigate parent‐reported psychiatric, neurodevelopmental and adaptive functioning outcomes in children with congenital cytomegalovirus (cCMV)‐related sensorineural hearing loss. Methods Parents of children aged 5–12 years were recruited nationwide in Sweden into three groups: children with congenital cytomegalovirus‐related ...
A. Michel Sandström   +2 more
wiley   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos   +4 more
wiley   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend   +16 more
wiley   +1 more source

The association between inborn errors of immunity and Hodgkin lymphoma—A register‐based case–control study in Sweden

open access: yesBritish Journal of Haematology, EarlyView.
Summary Immune dysfunction is implicated in the aetiology of Hodgkin lymphoma (HL), but the association between inborn errors of immunity (IEI) and HL remains poorly understood. We conducted a retrospective, register‐based case–control study in Sweden over five decades to investigate the relationship between IEI and HL. Individuals diagnosed with HL in
Agnes Winsa   +7 more
wiley   +1 more source

Long‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly (HALO trial)

open access: yesBritish Journal of Haematology, EarlyView.
Summary The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL.
Andrea Gallamini   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy